तुलना करने के लिए मीट्रिक्स | CHM | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCHMपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.1x | −3.8x | −0.4x | |
PEG अनुपात | 0.00 | −0.05 | 0.00 | |
क़ीमत/बुक | −0.7x | 1.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.2x | 13.6x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 210.6% | 53.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 29.6% | 9.0% | अनलॉक करें |
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.